STUDY QUESTION: Is the thrombophilia mutation factor V Leiden (FVL) associated with an increased total sperm count?
Introduction
Factor V Leiden (FVL) is a gain-of-function single point mutation (Arg506Gln) in the gene coding for factor V, one of the procoagulant proteins in the hemostatic system (Bertina et al., 1994) . It causes resistance of factor Va to inactivation by activated protein C, leading to a 'prothrombotic state' or thrombophilia. FVL increases the risk of venous thromboembolism, a potentially fatal disease if left untreated, by about 5-fold (Emmerich et al., 2001) . It is also associated with miscarriage (relative risk 1.8) (Rodger et al., 2014) . About 5% of Caucasians carry the mutation, with rates reported from 0 to 15%, depending on geography (Rees et al., 1995; van Mens et al., 2013) . This high prevalence is thought to reflect some evolutionary benefit of FVL that counteracts the detrimental effects on health in carriers (van Mens et al., 2013) . The second most common inherited thrombophilia is the prothrombin G20210A mutation with a prevalence of around 2% (Rosendaal et al., 1998) . It causes high levels of circulating prothrombin and is likewise associated with venous thromboembolism and possibly miscarriage (Rey et al., 2003; Coppens et al., 2006) .
In a large Dutch cohort study in which fecundity was assessed as time between marriage and first child in a time when modern contraception was not yet available, male carriers of FVL were 3.5-fold more likely to have a child within 1 year than non-carriers (van Dunné et al., 2006) . This finding is sometimes used to explain the apparent evolutionary paradox of the high prevalence of the mutation (van Mens et al., 2013) . The improved fecundity might be explained by augmented spermatogenesis. We have previously reported on a cohort in which FVL carriers ostensibly had higher total sperm counts than non-carriers, although no statistically significant difference was found (Cohn et al., 2010) .
The aim of the current study was to further investigate whether FVL was associated with increased total sperm count and to find a biological mechanism for the putative relation. As a secondary aim we tested the association between prothrombin G20210A mutation and total sperm count.
Materials and Methods

Study design and human populations
We included three cohorts of men in an individual patient data meta-analysis: two cohorts analyzed for the current study (Amsterdam 2 and Copenhagen) and one previously published cohort (Amsterdam 1) (Cohn et al., 2010) . Participants of the two Amsterdam cohorts were recruited consecutively, irrespective of their sperm count, from the Center for Reproductive Medicine of the Academic Medical Center, Amsterdam, the Netherlands, where they presented for a fertility workup for couples with subfertility. The first cohort (Amsterdam 1) was recruited between January 2000 and July 2007 and has been reported on previously (Cohn et al., 2010) . The second cohort (Amsterdam 2) had a recruitment period between July 2007 and December 2014. The third cohort (Copenhagen) consisted of consecutive men living in the Copenhagen area, Denmark, undergoing compulsory examination in the year of their 18th birthday to evaluate their fitness for military service. This cohort has previously been used to investigate other research questions (Jørgensen et al., 2012; Joensen et al., 2014) . At inclusion, FVL and prothrombin G20210A mutation status was unknown to the researchers.
Exclusion criteria for the cohorts in Amsterdam, aimed at excluding men with known causes for spermatic failure, comprised the following: hyperprolactinemia, hypogonadotrophic hypogonadism, previous chemoor radiotherapy, bilateral cryptorchidism, congenital absence or surgery of the vas deferens, history of orchitis, bilateral orchidectomy, retrograde ejaculation, azoospermia, a microdeletion in the azoospermia factor (AZF) region of the Y-chromosome, and numerical or structural chromosome abnormalities. Exclusion criteria in the Copenhagen cohort were hypogonadotrophic hypogonadism, current use of anabolic steroids and a history of chemotherapy-treated malignancy.
Ethical approval was, respectively, obtained from the Institutional Review Board of the Academic Medical Center and Danish National Committee on Biomedical Research Ethics. All men provided written informed consent.
Semen parameters and FVL and prothrombin G20210A mutation status Men were instructed to maintain ejaculation abstinence for 3 days in the Amsterdam cohorts and 48 h in the Copenhagen cohort. Actual selfreported abstinence time was recorded. Semen specimens were analyzed in a blinded fashion as previously described (Cohn et al., 2010; Joensen et al., 2014) in accordance with World Health Organization guidelines (World Health Organization Department of Reproductive Health and Research, 1992, 2010) . In the Amsterdam cohorts the average of at least two specimens with a minimum interval of 2 weeks was used. In the Copenhagen cohort a single specimen was used. Total sperm count was defined as sperm concentration multiplied by volume.
FVL (rs6025) and prothrombin G20210A mutation (rs1799963) were detected by PCR using commercially available primers (Thermo Fischer Scientific, Waltham, MA, USA) 
Mouse model
We compared heterozygous and homozygous mice carrying the murine R504Q equivalent of the human R506Q mutation (FVL) to wild-type males on a C57BL/6 background. Wild-type mice were purchased from Charles River Laboratories (Wilmington, MA, USA). FVL mice were described previously (Cui et al., 2000) and were maintained on the C57BL/6J background. Mice were between 15 and 18 weeks old and had never been bred. Parameters investigated were combined weight of internal genital organs (testes, epididymes and seminal vesicles) as a percentage of total body weight, sperm count and sperm motility. The mice were housed in the Animal Resource Center at the Medical College of Wisconsin, following procedures approved by the local Animal Care and Use Committee.
Mice were sacrificed by carbon dioxide asphyxiation and the testes, epididymes and seminal vesicles were dissected and weighed. Caudal parts of the epididymes were transected and minced with microscissors in a 100 μL drop of a human tubal fluid fertilization medium which was preequilibrated at 37.5°C in 5% CO 2 and subsequently covered with mineral oil. The sperm suspensions were incubated at 37°C in air for 3 min and after careful mixing, and a 1:10 dilution of the sperm-containing medium was pipetted onto a four chamber microscope slide and investigated using an Olympus BX41 microscope. Sperm concentration and motility were determined as the average of seven random fields, with fields containing cell clumps being ignored, using computer-assisted sperm analysis (SpermVision ® , MOFA). Total sperm count was calculated from the reported concentration using the volumes and dilutions of the medium, representing the total count in the caudal epididymes.
Genetic linkage
We explored the public haplotype data from subjects of European descent in Hapmap and 1000 Genomes Project. Using Haploview software we tested linkage disequilibrium of FVL with all known single nucleotide polymorphisms (SNPs) in a 1.5 MB region around the F5 gene. SNPs were identified as potentially linked with an R 2 cutoff of 0.8.
We furthermore selected the subgroup of Dutch FVL carriers with a sperm count of over 500 * 10 6 cells per ejaculation and sequenced exons of candidate genes. Selection of candidate genes, from a 6 Mb region around F5, was based on genetic proximity to the factor V gene and a known or suspected role in spermatogenesis, and comprised: maelstrom spermatogenic transposon silencer (MAEL), solute carrier family 19 (thiamine transporter), member 2 (SLC19A2), NME/NM23 family member 7 (NME7) and selectin P (SELP). Genes that were considered are listed in Supplementary Table SI. After amplification of genomic DNA by PCR, we sequenced the PCR products of all exons of these candidate genes bidirectionally using Big Dye Terminator chemistry and the Genetic Analyzer 3730 system (Applied Biosystems, Foster City, CA, USA) (primers listed in Supplementary  Table SII) . We reviewed these sequences manually with Sequencher software (GeneCodes Co, Ann Arbor, MI, USA). SNPs in these genes that were present in more than two-thirds of the men were evaluated against the prevalence in the Dutch population as found in the Genome of the Netherlands project (Genome of the Netherlands Consortium, 2014). If the frequency of occurrence of the SNP in our subgroup was more than 5-fold that in the general population, we considered this a potential SNP of interest and genotyped this SNP in an extended cohort.
Statistical analysis
The main outcome of the study was total sperm count in FVL carriers compared to non-carriers. For the primary analysis, we performed individual patient data meta-analysis using a predefined linear mixed model to achieve an adjusted mean difference. Current smoking, age and abstinence time were included as fixed effects. To take into account differences in the source population, cohort was added as a random (intercept) effect. We obtained P-values by likelihood ratio test of the model against the same model without FVL as a predictor variable. This analysis and kernel density estimations were performed in R version 3.3.1 (R Foundation for Statistical Computing, Vienna, Austria). Forest plots and unadjusted pooled estimates were obtained with Review Manager (RevMan. Version 5.3. The Nordic Cochrane Centre, The Cochrane Collaboration, Copenhagen, Denmark). Parametric and non-parametric inferential and descriptive statistics were used where appropriate. A value of P < 0.05 was considered significant.
Results
Participants and baseline characteristics
The total number of participants from the three cohorts available for individual patient data meta-analysis was 2389, excluding a total of 52 men for whom sperm count was not available. The sample sizes in each cohort were as follows: Amsterdam 1: n = 908; Amsterdam 2: n = 627; Copenhagen: n = 854. The baseline characteristics are displayed in Table I . Danish participants were younger, had a shorter period of abstinence and a higher frequency of current smoking (all P < 0.001). These differences were taken into account in the primary analysis. The prevalence of FVL was 4.0%, 4.6% and 7.3% in cohorts Amsterdam 1, Amsterdam 2 and Copenhagen, respectively, while the prevalence of prothrombin G20210A mutation was 1.7%, 2.2% and 1.5%, respectively. One homozygous FVL carrier was identified in the Amsterdam 2 cohort.
Sperm counts in human mutation carriers Figure 1 displays the density estimations of total sperm count in FVL carriers versus non-carriers for the three separate cohorts and the combined cohort. A bimodal distribution of the density estimations is observed in carriers but not in non-carriers.
In the primary analysis the adjusted mean difference in total sperm count between FVL carriers and non-carriers was 31.0 × 10 6 (95%CI 0.2-61.7; P = 0.048). Prothrombin G20210A mutation carriership was not associated with total sperm count (P = 0.57). Mean sperm counts for carriers and non-carriers in the individual cohorts are displayed in Fig. 2 , for both FLV and prothrombin G20210A mutations, along with the unadjusted pooled estimates of the mean difference.
Mouse model
We investigated spermatogenesis parameters in mice heterozygous (n = 9) and homozygous (n = 5) for FVL relative to wild type (n = 7). One wild-type mouse was disregarded because of a pathologically swollen epididymis at dissection. There were no differences in normalized weight of reproductive organs, or in caudal epididymis sperm count or motility (Table II) . *These data have previously been reported (Cohn, Repping, Büller, Meijers, & Middeldorp, 2010) ; **Morphology was determined according to WHO 1992 criteria (World Health Organization, 1992 in the Amsterdam cohorts and by WHO 2010 criteria (World Health Organization, 2010 in the Copenhagen cohort and are therefore not directly comparable. ***P < 0.001 by Kruskal-Wallis test; ****P < 0.001 by chi-squared test. FVL, factor V Leiden; IQR, interquartile range; PGM, prothrombin G20210A mutation.
Genetic linkage
Both the fact that prothrombin G20210A mutation, which has comparable biochemical effects to FVL in terms of thrombin generation in plasma, is not associated with increased or decreased sperm count, and the absence of an effect of FVL on sperm count in the mouse model, suggest that perhaps there is no direct causality underlying the identified association between sperm count and FVL in humans. The apparent bimodal distribution of the density estimations (Fig. 1) might reflect a subgroup of FVL carriers with high sperm counts that drives the difference with non-carriers. We therefore hypothesized that FVL was associated with elevated sperm counts through linkage with a causal polymorphism, and that this polymorphism could be identified in the subgroup of FVL carriers with sperm counts over 500 × 10 6 .
In the public haplotype databases no known exonic SNPs in a 1.5 MB region around the F5 gene were in linkage disequilibrium with FVL at an R 2 cutoff of 0.8.
Exon sequencing of candidate genes was performed in the subgroup of six FVL-carrying Dutch men with total sperm counts of over a 500 × 10 6 cells. The most common variant found was the intronic variant rs61535831 in a region flanking exon 7 of the SELP gene. It was present in all six men but also had a prevalence of 50.3% in the Dutch population. Another variant in SELP, rs6131, was present in four of the six men and had a prevalence of 19.0% in the Dutch population. Neither variant was therefore considered as a potential SNP of interest. Other variants identified had lower occurrence in the subgroup and/or higher prevalence in the general population and were therefore deemed unlikely to be the hypothesized causal polymorphism (Supplementary  Table SIII) .
Discussion
In the current study we have established the association between FVL carriership and increased total sperm counts in three independent cohorts of men (adjusted mean difference 31.0 × 10 6 , P = 0.048). This finding could form a partial explanation for the evolutionary paradox of the high prevalence of FVL despite its disadvantageous phenotype. Although the association was shown with borderline statistical significance, no regression to the mean was manifest in separate observations. In our previous publication, Dutch FVL carriers in both a pilot study and a subsequent formal cohort study (Amsterdam 1) had higher sperm counts. This trend (in the individual cohorts the difference is not statistically significant) was again observed in a second sample of the same population (Amsterdam 2), as well as in an unrelated Danish cohort (Copenhagen).
The hypothesis of an elevated sperm count in FVL carriers was based on previous observations (Cohn et al., 2010) . In order to achieve sufficient power on the one hand, and to increase generalizability of the findings on the other, we chose to include a Danish study population as well as the original Dutch cohort and its extension, cohort Amsterdam 2. The trend in the Copenhagen cohort (median count in FVL carriers 157.1 (IQR 84.0-256.8) versus non-carriers 144.2 (IQR 68.2-280.0)) was found to be less pronounced than in the Amsterdam 1 and 2 cohorts. Aside from the statistical uncertainty, this might be a reflection of several differences in study design and source population. The Amsterdam cohorts consisted of men of subfertile couples, whereas the Copenhagen cohort comprised healthy men around 19 years of age. Consequently there were differences in baseline characteristics, most notably age and smoking. We have dealt with this by performing multiple regression, at an individual patient level, in the primary analysis, enabling correction for this variation. The applied mixed effect model furthermore incorporated unidentified differences by treating the cohort as a random effect. The random effect essentially corrects for the cohort specific variation that is not measured by the baseline variables in the model. This is especially important if the underlying mechanism is thought to be genetic linkage. The effect size of FVL carriership would then depend on the linkage disequilibrium with the causal polymorphism, which could well vary between populations with different genetic backgrounds, requiring random effects modeling.
The mechanism behind the association remains elusive. Although the biochemical effects of FVL in plasma are well characterized (Segers et al., 2007) , little is known about coagulation factors in seminal plasma. Some have suggested that a system similar to plasmatic secondary hemostasis is in place that controls coagulation and liquefaction of semen (Lwaleed et al., 2007b) . Coagulation factors are present in seminal plasma (Lwaleed et al., 2007a) . Factor VIIa levels have been linked to semen volume but not to total sperm count (Lwaleed et al., 2007b) . D-dimer and thrombin-antithrombin complex concentrations in semen were lower in men with infertile semen compared to controls (van Wersch et al., 1992) . Protein C inhibitor appears to have a role in reproduction, with knock-out mice displaying abnormal spermatogenesis and infertility (Uhrin et al., 2000; Meijers and Herwald, 2011) . Activated protein C plasma levels are sometimes thought to be increased in FVL carriers (van Mens et al., 2017) . If the same is true for seminal plasma then an interaction between this multifunctional protein and its natural inhibitor might be investigated in the light of our current findings. We have previously studied protein C inhibitor for mutations in men with low sperm counts but were unable to find significant mutations (Gianotten et al., 2004) . However, at this point we can only speculate on the (patho)physiological basis. One potentially informative piece of evidence is the absence of an association between sperm count and prothrombin G20210A mutation. Like FVL, prothrombin G20210A mutation leads to increased thrombin generation and thus coagulation, albeit through a different mechanism. This might suggest that the spermatogenic effect of FVL does not occur through hypercoagulability.
Furthermore, FVL mice in our study did not show altered parameters of spermatogenesis. Although murine findings cannot be directly translated to observations in humans, the inability of experimentally induced FVL to reproduce the increase in sperm count could mean that the association is not directly causal. At the same time, the possibility of the finding being an artifact through confounding is very unlikely, since determinants of sperm count, such as smoking or abstinence time, will be independent of FVL and men were not aware of their FVL status.
Genetic linkage then becomes an attractive hypothesis. FVL might be in linkage disequilibrium with a genetic variant that is the actual causal factor in the observed relation. The density estimations appear to display a bimodal distribution in FVL carriers only, which might be taken to reflect a subgroup of men that drive the effect. These men were further analyzed to find this hypothesized SNP of interest. We did not identify rare variants in exons of selected candidate genes for which they were all carriers, and thus the hypothesis was not confirmed. We furthermore did not identify, through publicly accessible databases, any SNPs in the vicinity of the FV gene that were in linkage disequilibrium with FVL. These explorative efforts unfortunately do not suffice to rule out genetic linkage as an explanation, which would require a greater sample size and complete sequencing of a larger genetic region.
In conclusion, we have confirmed that the inherited thrombophilia mutation FVL is associated with higher total sperm counts in three pooled European cohorts. The association was shown with borderline significance and would thus benefit from confirmation in additional cohorts, where studying other populations would be especially informative. Although studied extensively, the underlying mechanism of this relation could not be identified. Both hypercoagulability of seminal plasma and genetic linkage might be further investigated in this light. Nonetheless a high sperm count in FVL-carrying males, also with no definitive explanation, contributes to understanding the high prevalence of this mutation. The findings might provide directions for future research on male fertility.
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